Substance P doesn't just cause pain — depending on which ion channels and cell types are involved, this neuropeptide can also suppress it, potentially offering a new pathway for painkiller development.
Dual roleSubstance P can both cause and relieve pain depending on the ion channels and cell types involved in NK1 receptor signaling
What the researchers found
Substance P, an 11-amino-acid neuropeptide long assumed to only cause pain, actually plays a paradoxical dual role — it can both promote pain (nociception) and suppress it (anti-nociception). The direction of its effect depends on which ion channels it modulates and which cell types express the NK1 receptor.
The review maps how SP activates different downstream signaling pathways through NK1 receptors in different cell types, engaging calcium channels, potassium channels, and other ion channels to produce opposite pain outcomes. This dual nature suggests that targeting the anti-nociceptive SP-NK1R pathway could lead to a new class of painkillers.
Why it matters
Pain management remains one of the biggest challenges in medicine, with opioid alternatives urgently needed. If substance P — one of the most studied neuropeptides — can actually suppress pain under certain conditions, understanding exactly how could open an entirely new approach to analgesic drug design based on channeling SP's anti-pain pathway rather than blocking it entirely.
The numbers in context
11 amino acids (substance P length) · NK1R receptor · Calcium and potassium channels involved · Review of both pro-pain and anti-pain pathways
How the study worked
This is a narrative review of published studies examining substance P's role in pain signaling. The authors analyzed evidence on SP-modulated ion channels (calcium, potassium, and others), NK1 receptor signaling in different cell types, and the differential downstream effector systems that determine whether SP produces pain or pain relief.
Who was studied
Review of human and animal studies on substance P signaling in pain pathways
What this study cannot tell us
As a narrative review, this paper synthesizes existing literature without new experimental data. Much of the anti-nociceptive evidence comes from animal models, and the conditions under which SP suppresses vs. promotes pain in humans are not yet fully defined. The clinical translatability of the anti-nociceptive pathway remains theoretical.
How to read the evidence
This is a well-structured review in a peer-reviewed journal that synthesizes evidence from multiple studies on both nociceptive and anti-nociceptive substance P pathways. The evidence is moderate because the anti-nociceptive mechanisms are established in animal models but not yet validated in human clinical settings.
When this study was published
Published in 2019, this review reflects a relatively recent understanding of substance P's dual role in pain. The anti-nociceptive pathway it highlights remains an active area of research and drug development.
The bigger picture
The opioid crisis has made finding non-opioid painkillers one of medicine's top priorities. NK1 receptor antagonists (which block substance P) were developed as painkillers but largely failed in clinical trials — perhaps because they blocked both the pain-causing AND pain-relieving actions of SP. This review suggests a more nuanced approach: instead of blocking SP entirely, selectively activate its anti-nociceptive pathway. This represents a paradigm shift in how we think about neuropeptide-based pain therapy.
Questions still open
- Could drugs be designed to selectively activate substance P's anti-nociceptive pathway while leaving its pro-pain signaling untouched?
- Does the failure of NK1 receptor antagonists as painkillers in clinical trials reflect the accidental blockade of SP's pain-relieving effects?
- Which specific ion channel subtypes mediate SP's anti-nociceptive effect, and are they druggable targets?
Common questions
How can the same peptide both cause and stop pain?
Why did substance P-blocking painkillers fail in clinical trials?
Read the original research
Ion Channels Involved in Substance P-Mediated Nociception and Antinociception.
International journal of molecular sciences, 20(7)
Citation
Chang, Chu-Ting; Jiang, Bo-Yang; Chen, Chih-Cheng. (2019). Ion Channels Involved in Substance P-Mediated Nociception and Antinociception.. International journal of molecular sciences, 20(7). https://doi.org/10.3390/ijms20071596